Clinical trials: Hepatic Tumors
Carcinoma, Hepatocellular
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
The aim of the study is to investigate the safety, tolerability, efficacy and pharmacokinetics (PK) for Japanese hepatocellular carcinoma which are not amenable to curative surgery or loco regional therapy
- Trial name
- NCT01594125
- Testing
- Nintedanib high dose, Nintedanib low dose, Nintedanib medium dose
- Where
- 5 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Hepatocellular Carcinoma
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
- Trial name
- NCT07691762
- Testing
- SHR-8068 + Adebrelimab + Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 690 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams…
- Trial name
- NCT04953910
- Testing
- ASTX727
- Where
- 22 sites in United States, Armenia and 6 more
- Volunteers
- 27 people
- Sponsor
- Taiho Oncology, Inc.
Carcinoma, Hepatocellular
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
This multicenter, open-label study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicities of onartuzumab as single agent or in combination with sorafenib in participants with advanced hepatocellular…
- Trial name
- NCT01897038
- Testing
- Onartuzumab, Sorafenib
- Where
- 10 sites in United States, Hong Kong and 2 more
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Hepatocellular
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find out if sorafenib has any effect on patient reported outcomes.
- Trial name
- SHARP (NCT00105443)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 178 sites in United States, Argentina and 21 more
- Volunteers
- 602 people
- Sponsor
- Bayer
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Solid Tumor, Lung Cancer
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
This is a single arm study to evaluate the efficacy and safety of CEA-targeted CAR-T cells therapy for patients with relapsed/refractory CEA+ Cancer,and obtain the recommended dose and infusion plan.
- Conditions
- Solid Tumor, Lung Cancer, Colorectal Cancer, Liver Cancer
- Trial name
- NCT04348643
- Testing
- CEA CAR-T cells
- Where
- 2 sites in China
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT07713290
- Testing
- GKL-006 Injection, Transarterial chemoembolization (TACE)
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Hepatocellular Carcinoma
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 open-label, single-arm, non-randomized study in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with sorafenib using a Simon's 2-stage design.
- Trial name
- NCT01752933
- Testing
- SGI-110
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 52 people
- Sponsor
- Astex Pharmaceuticals, Inc.